Marisa Wexler, MS,  senior science writer—

A variation in a gene called STK11, previously shown to increase the risk for multiple sclerosis (MS) among Caucasians, is now also linked to a greater likelihood of MS in Black people. In fact, the variation was significantly more common in Black MS patients with secondary progressive MS (SPMS),…

PoNS, a non-invasive devise to accompany physical therapy in multiple sclerosis (MS) patients with difficulty walking, will be available on the U.S. market early next year, its developer, Helius Medical Technologies, announced in a quarterly financial update. Short for Portable Neuromodulation Stimulator, the PoNS…

A smartphone-based app called Floodlight can reliably assess cognition, arm and hand function, and walking abilities in people with multiple sclerosis (MS), according to new analyses. “Detection of progression onset or worsening is critical to optimally adapt the therapeutic strategy” patients are using to treat the neurodegenerative disease,…

A Phase 3 clinical trial testing the effect of Ocrevus (ocrelizumab) on upper limb disability progression in people with primary progressive multiple sclerosis (PPMS) is recruiting participants. The trial, called O’HAND (NCT04035005), expects to enroll approximately 1,000 adults with PPMS, ages 18 to 65, at more than…

Probiotic supplements could ease disability, lessen depression, and improve overall health in people with relapsing-remitting multiple sclerosis (MS), according to an analysis of four randomized clinical trials. Physicians working with these patients might recommend “confirmed probiotic supplements” to help manage “MS concerns,” its scientists wrote, while noting that studies…

Lemtrada (alemtuzumab) does not have a substantial effect on blood pressure or platelet counts, and does not lead to bleeding in the brain of multiple sclerosis (MS) patients, according to a small Belgian study. The findings contrast with previous studies showing an increase in blood pressure, stroke, and…

Visits to the hospital related to multiple sclerosis (MS) are more common when it’s hot or when temperatures are more variable, but less likely to be needed when it’s humid, a new analysis suggests. The results were published in the International Journal of Environmental Research and Public Health, in…

More than half of people with multiple sclerosis (MS) who require an informal caregiver have experienced abuse or mistreatment by that caregiver, according to a study conducted in California. The study, “Validity and Reliability of the Scale to Report Emotional Stress Signs–Multiple Sclerosis (STRESS-MS) in Assessing…

More than one-third of people with multiple sclerosis (MS) who responded to an online U.S.-based survey are dissatisfied with their quality of life, and more than one in four MS patients are pessimistic about their future, according to the results of the survey, conducted by Multiple Sclerosis News…

Treatment with the diabetes medication metformin was seen to lessen cognitive impairment, improve coordination, and normalize neuronal activity in a rat model of multiple sclerosis (MS). The study reporting these findings, “Evaluation of the effects of metformin as adenosine monophosphate-activated protein kinase activator on spatial learning and…

A signaling protein called fractalkine helps to regulate the development of oligodendrocytes, cells of the nervous system responsible for making myelin — the protecting coating of nerve cell fibers that is damaged and lost in multiple sclerosis (MS). This finding was in the study, “Fractalkine signaling regulates…

Subtle changes in structure in the hippocampus — a region of the brain involved in processing memories — can differentiate between relapsing-remitting and primary progressive multiple sclerosis, according to a new study. The study, “Unraveling the MRI-Based Microstructural Signatures Behind Primary Progressive and Relapsing–Remitting Multiple Sclerosis Phenotypes,”…

People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier stage in their disease in recent years, compared to individuals who switched to the treatment around the time it became available, a new study indicates. The findings suggest “an increased experience in…

NervGen Pharma announced the formation of its multiple sclerosis (MS) clinical advisory board, a group of experts who will work with the company as it prepares to start a Phase 2 clinical trial next year testing its lead compound, NVG-291, in people with MS. “We are honored to…

Treatment with anti-CD20 antibodies reduced the loss of myelin and improved the survival of neurons in a rat model of multiple sclerosis (MS), a new study reports. The findings imply that B-cells — the immune cells that are killed by anti-CD20 antibodies — play a central role in the…

The U.S. Food and Drug Administration has cleared Immunic Therapeutics to initiate two clinical trials of its investigational medication IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS), as well as a separate trial for people with progressive types of MS. The RRMS clinical trial program, expected…

In clinical trials, the investigational anti-CD20 therapy ublituximab was the first to push the annualized relapse rate (ARR) below the 0.1 threshold among patients with relapsing forms of multiple sclerosis (MS), while improving disability outcomes in a significant proportion of patients. “The [relapse] rate was below a tenth…

Long-term disability outcomes tend to be better in people with relapsing-remitting multiple sclerosis (RRMS) who are treated early on with highly effective therapies, a study based on patient registry data indicates. The study, “Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or…

Many people with multiple sclerosis (MS) start experiencing symptoms of the disease several years before being diagnosed, a new study suggests. While it has long been known that people with MS tend to seek medical attention more frequently in the years before diagnosis than those without the disease, there…

Long-term use of Kesimpta (ofatumumab) among people with multiple sclerosis (MS) did not substantially lower their antibody levels, allowing them to retain an ability to fight infections, new data from a Phase 3 clinical trial indicate. “These long-term results continue to support Kesimpta as a high-efficacy, first-choice treatment with…

The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing-remitting multiple sclerosis (RRMS). Aubagio, approved for adults with RRMS since 2013, is now the first oral therapy available as a first-line treatment for pediatric patients in the European…

In the OPTIMUM clinical trial, Ponvory (ponesimod) significantly outperformed Aubagio (teriflunomide) in reducing relapse rates, fatigue, and evidence of brain damage among people with relapsing multiple sclerosis (MS). Based on these results, Ponvory has now been approved in the U.S. and the European Union as a treatment…

T-cells in the fluid around the brain share a large percentage of receptors among different multiple sclerosis (MS) patients, a new report suggests. Better understanding the diversity of T-cell receptors in MS, and how these cells vary in different parts of the body, could be useful in understanding the…

The U.S. Food and Drug Administration (FDA) has rejected an application requesting the expansion of Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing forms of multiple sclerosis (MS). “The FDA deemed the data submitted were not sufficient to obtain approval of…

A computer-based training program that exercises distinct components of attention and working memory can improve cognition in young people with pediatric-onset multiple sclerosis (POMS), a new study indicates. Findings also support a common pencil-and-paper measure of cognition, called the Symbol Digit Modalities Test (SDMT), in detecting clinically meaningful changes…

Nearly a third of people with multiple sclerosis (MS) who are younger than 40 are not being treated with disease-modifying treatments (DMTs), even though younger individuals are expected to get the most benefit from DMTs, according to a new study. “DMTs for MS are more frequently used at…

Immersive virtual reality may make treadmill exercise more engaging and effective for people with multiple sclerosis (MS) or other conditions that can make walking difficult, according to new research. The findings were published in the Journal of NeuroEngineering and Rehabilitation, in the study “Immersive virtual reality…

Due to differences in sex chromosomes, certain immune cells cause more severe disease in males than females, according to a new study in a mouse model of multiple sclerosis (MS). The findings could help to explain why biological males with MS tend to have more severe disease. The study,…

Treatment with Mavenclad (clabridine) reduces the frequency of relapses in people with relapsing-remitting multiple sclerosis (RRMS), with benefits appearing to be evident two years after patients stopped taking the treatment, new data suggest. These findings were in the study, “Analysis of frequency and severity of relapses…

A new 3D model of the human nervous system is meant to mimic key processes in the development of the myelin sheath — the fatty coating around nerve cells that is damaged in multiple sclerosis (MS) — to help with research into treatments that promote myelination. This model might also…